A PK study of ND0612, comparing infusion sites and cannula lengths
Research type
Research Study
Full title
An Open-Label, Randomized, Single-dose, 4-Period, Crossover Study to Compare the Pharmacokinetics of Subcutaneous ND0612 Administered at Different Infusion Sites and Two Different Cannula Lengths in Healthy Male and Female Subjects
IRAS ID
242559
Contact name
Muna Albayaty
Contact email
Sponsor organisation
NeuroDerm Ltd.
Eudract number
2018-000385-10
Duration of Study in the UK
0 years, 1 months, 29 days
Research summary
The compound tested in this study, ND0612, is being developed by NeuroDerm to treat patients with Parkinson’s Disease (PD). The standard treatments for PD are levodopa and cardiopa which function by ensuring a steady level of dopamine in the brain. Dopamine is a brain messenger associated with movement control, and research suggests that symptoms of PD are related to a lack of dopamine in certain areas of the brain. \n\nNeuroDerm is developing ND0612 as continuous infusion to treat motor fluctuations in patients with advanced PD. The study will assess the impact of infusion sites and cannula length on the concentration of the drug in the plasma.\n\n\n
REC name
London - Brent Research Ethics Committee
REC reference
18/LO/0246
Date of REC Opinion
10 Apr 2018
REC opinion
Further Information Favourable Opinion